Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy

Zhou, Caicun; Wang, Yina; Zhao, Jun; Chen, Gongyan; Liu, Zhihua; Gu, Kangsheng; Huang, Meijuan; He, Jianxing; Chen, Jianhua; Ma, Zhiyong; Feng, Jifeng; Shi, Jianhua; Yu, Xinmin; Cheng, Ying Ying; Yao, Yu Si; Chen, Yuan Yuan; Guo, Renhua; Lin, Xiaoyan; Wang, Zhehai; Gao, Guanghui; Wang, Quanren; Li, Weixia; Yang, Xinfeng; Wu, Lihong; Zhang, Jun; Ren, Shengxiang

doi:10.1158/1078-0432.CCR-20-3136

Record: found
Abstract: not found
Article: not found

Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy

Author(s): Caicun Zhou , Yina Wang , Jun Zhao , Gongyan Chen , Zhihua Liu , Kangsheng Gu , Meijuan Huang , Jianxing He , Jianhua Chen , Zhiyong Ma , Jifeng Feng , Jianhua Shi , Xinmin Yu , Ying Cheng , Yu Yao , Yuan Chen , Renhua Guo , Xiaoyan Lin , Zhehai Wang , Guanghui Gao , Quanren Wang , Weixia Li , Xinfeng Yang , Lihong Wu , Jun Zhang , Shengxiang Ren

Publication date Created: March 01 2021

Publication date (Electronic): December 15 2020

Journal: Clinical Cancer Research

Publisher: American Association for Cancer Research (AACR)

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Most cited references 45

Record: found
Abstract: found
Article: not found

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodriguez-Abreu, Andrew G Robinson … (2016)

Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1).

0 comments Cited 2930 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Hossein Borghaei, Luis Paz-Ares, Leora Horn … (2015)

Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.

0 comments Cited 2423 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Roy S. Herbst, Paul Baas, Dong-Wan Kim … (2016)

Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.

0 comments Cited 1785 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Renhua Guo: (View ORCID Profile)

Journal

Title: Clinical Cancer Research

Abbreviated Title: Clin Cancer Res

Publisher: American Association for Cancer Research (AACR)

ISSN (Print): 1078-0432

ISSN (Electronic): 1557-3265

Publication date Created: March 01 2021

Publication date (Print): March 01 2021

Publication date (Electronic): December 15 2020

Volume: 27

Issue: 5

Pages: 1296-1304

Article

DOI: 10.1158/1078-0432.CCR-20-3136

PubMed ID: 33323401

SO-VID: 7537f77e-d4ff-40eb-aa18-ba00d3415479

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.